Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to ‘Jahrsdorfer et al.’

Leukemia volume 21, pages 2355–2356 (2007)Cite this article

Sensitivity to CpG ODN-induced apoptosis was additionally investigated in selected cases by analysis of PARP cleavage. These data are now presented in Figure 1b and confirm that certain CLL cases, mainly those with progressive disease and unmutated VH genes, are resistant to CpG ODN-induced apoptosis. Together, these observations lead us to suggest that CpG ODN may not be effective in a subset of poor prognosis patients, unless pathways that regulate pro-survival signaling are not blocked simultaneously. However, we agree with Jahrsdorfer et al. that the absence of a direct apoptotic effect in vitro does not exclude the possibility that CpG ODN may still be beneficial because of other modes of action, such as the enhancement of an immunostimulatory phenotype. Further experimental work and the results of ongoing clinical trials will hopefully resolve this issue.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110–120.

    Article  CAS  Google Scholar 

  2. Jahrsdorfer B, Blackwell S, Weiner GJ . The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could impact on its clinical utility. Leukemia 2007.

Download references

Author information

Authors and Affiliations

  1. ICGEB Molecular Hematology Group, Monterotondo-Outstation, CNR Campus ‘A Buzzati-Traverso’, Rome, Italy

    P G Longo, S Gobessi & D G Efremov

Authors
  1. P G Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Gobessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D G Efremov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D G Efremov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Longo, P., Gobessi, S. & Efremov, D. Reply to ‘Jahrsdorfer et al.’. Leukemia 21, 2355–2356 (2007). https://doi.org/10.1038/sj.leu.2404871

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404871

Search

Advanced search

Quick links